Patents by Inventor Triparna Sen

Triparna Sen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treating Cancer with Chk1 Inhibitors
    Publication number: 20220184091
    Abstract: Disclosed herein are methods of treatment by administering SRA737 as a monotherapy or in a combination therapy that is useful for treating patients with cancer.
    Type: Application
    Filed: March 26, 2020
    Publication date: June 16, 2022
    Applicants: Sierra Oncology, Inc., The University of Texas M.D. Anderson Cancer Center
    Inventors: Christian Andrew Hassig, Snezana Milutinovic, Ryan James Hansen, Bryan William Strouse, Lauren Byers, Triparna Sen
  • Synergistic liposomal formulation for the treatment of cancer
    Patent number: 10426728
    Abstract: The present disclosure relates to the synergistic liposomal formulation comprising, phophatidylcholine, stearylamine and anticancer drugs for the treatment of cancer. The PC:SA cationic liposome encapsulated camptothecin (CPT) and doxorubicin (DOX) formulations show enhanced synergistic anti-cancer effect and provide improved therapeutic index as compared to either the liposome or drug alone. The present disclosure also relates to the use of Cationic liposomal preparation of phosphatidylcholine:stearylamine (PC:SA) showing anticancer effect. The SA-bearing liposome and drug entrapped in the liposome are effective against cancer both in vitro and in vivo, without causing any adverse effect on host.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: October 1, 2019
    Assignee: Council of Scientific and Industrial Research
    Inventors: Nahid Ali, Manjarika De, Triparna Sen
  • SYNERGISTIC LIPOSOMAL FORMULATION FOR THE TREATMENT OF CANCER
    Publication number: 20160228366
    Abstract: The present disclosure relates to the synergistic liposomal formulation comprising, phophatidylcholine, stearylamine and anticancer drugs for the treatment of cancer. The PC:SA cationic liposome encapsulated camptothecin (CPT) and doxorubicin (DOX) formulations show enhanced synergistic anti-cancer effect and provide improved therapeutic index as compared to either the liposome or drug alone. The present disclosure also relates to the use of Cationic liposomal preparation of phosphatidylcholine:stearylamine (PC:SA) showing anticancer effect. The SA-bearing liposome and drug entrapped in the liposome are effective against cancer both in vitro and in vivo, without causing any adverse effect on host.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 11, 2016
    Inventors: Nahid Ali, Manjarika De, Triparna Sen